Tech Company Inital Public Offerings
Viela Bio IPO
Viela Bio was acquired by . Shares started trading on 10/2/2019.
Transaction Overview
Company Name
Announced On
10/2/2019
Transaction Type
IPO
Amount
$150,100,000
Proceeds Purpose
Management says it will use the net proceeds from the IPO as follows: to support our activities for our BLA approval process for inebilizumab and to conduct pre-commercial and commercial launch activities; to conduct clinical trials for inebilizumab in additional indications; to advance development of VIB4920; to advance development of VIB7734; and the balance for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 MedImmune Way 5th Floor
Gaithersburg, MD 20878
USA
Gaithersburg, MD 20878
USA
Phone
Undisclosed
Website
Email Address
Overview
Viela Bio (Nasdaq: VIE) is a biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bing Yao
Chief Medical Officer
Jorn Drappa
VP - Bus. Development
William Ragatz
VP - Bus. Development
Aaron Ren
VP - Finance
Mitchell Chan
VP - Human Resources
Kate Surdez
VP - Marketing
Maureen Menacher
VP - Operations
Yang Wang
VP - Regulatory Affairs
Soraya Madani
Browse more venture capital transactions:
Prev: 10/2/2019: NatureBox venture capital transaction
Next: 10/2/2019: Relativity Space venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs